1. Buchachart K, Krudsood S, Singhasivanon P, Treeprasertsuk S, Phophak N, Srivilairit S, Chalermrut K, Rattanapong Y, Supeeranuntha L, Wilairatana P, Brittenham G, Looareesuwan S: Effect of primaquine standard dose (15 mg/day for 14 days) in the treatment of vivax malaria patients in Thailand. Southeast Asian J Trop Med Public Health. 2001, 32: 720-726.
2. Beutler E: The hemolytic effect of primaquine and related compounds: a review. Blood. 1959, 14: 103-139.
3. Alving AS, Kellermeyer RW, Tarlov A, Schrier S, Carson PE: Biochemical and genetic aspects of primaquine-sensitive hemolytic anemia. Ann Intern Med. 1958, 49: 240-248.
4. Bolchoz LJ, Budinsky RA, McMillan DC, Jollow DJ: Primaquine-induced hemolytic anemia: formation and hemotoxicity of the arylhydroxylamine metabolite 6-methoxy-8-hydroxylaminoquinoline. J Pharmacol Exp Ther. 2001, 297: 509-515.
5. Schmidt LH: Appraisals of compounds of diverse chemical classes for capacities to cure infections with sporozoites of Plasmodium cynomolgi. Am J Trop Med Hyg. 1983, 32: 231-257.